Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors.

Journal: International journal of molecular sciences
PMID:

Abstract

Chimeric antigen receptor (CAR) T cells represent a revolutionary immunotherapy that allows specific tumor recognition by a unique single-chain fragment variable (scFv) derived from monoclonal antibodies (mAbs). scFv selection is consequently a fundamental step for CAR construction, to ensure accurate and effective CAR signaling toward tumor antigen binding. However, conventional in vitro and in vivo biological approaches to compare different scFv-derived CARs are expensive and labor-intensive. With the aim to predict the finest scFv binding before CAR-T cell engineering, we performed artificial intelligence (AI)-guided molecular docking and steered molecular dynamics analysis of different anti-CD30 mAb clones. Virtual computational scFv screening showed comparable results to surface plasmon resonance (SPR) and functional CAR-T cell in vitro and in vivo assays, respectively, in terms of binding capacity and anti-tumor efficacy. The proposed fast and low-cost in silico analysis has the potential to advance the development of novel CAR constructs, with a substantial impact on reducing time, costs, and the need for laboratory animal use.

Authors

  • Nico Martarelli
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Michela Capurro
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Gizem Mansour
    Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy.
  • Ramina Vossoughi Jahromi
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Arianna Stella
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Roberta Rossi
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Emanuele Longetti
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Barbara Bigerna
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Marco Gentili
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Ariele Rosseto
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Riccardo Rossi
    Department of Civil Environmental and Architectural Engineering, University of Padua, Via Marzolo 9, 35131 Padua, Italy.
  • Chiara Cencini
    Department of Chemistry, Biology, and Biotechnologies, Via del Giochetto, University of Perugia, 06122 Perugia, Italy.
  • Carla Emiliani
    Department of Chemistry, Biology, and Biotechnologies, Via del Giochetto, University of Perugia, 06122 Perugia, Italy.
  • Sabata Martino
    Department of Chemistry, Biology, and Biotechnologies, Via del Giochetto, University of Perugia, 06122 Perugia, Italy.
  • Marten Beeg
    Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy.
  • Marco Gobbi
    Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy.
  • Enrico Tiacci
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Brunangelo Falini
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.
  • Francesco Morena
    Department of Chemistry, Biology, and Biotechnologies, Via del Giochetto, University of Perugia, 06122 Perugia, Italy.
  • Vincenzo Maria Perriello
    Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy.